Pediatric Game Changers*: Topical calcineurin inhibitors for pediatric periorificial dermatitis



*A game changer is a short narrative stating how an article that originally appeared in *JAAD* changed the game of dermatology. **NOTE:** The Game Changer author is not the original author of the article. Please see the reference section for the original author information.

Julie V. Schaffer, MD Hackensack, New Jersey

Capsule Summary:

- The mainstay of treatment for periorificial dermatitis in the pediatric population includes topical and oral antibiotics, with very limited reports on topical calcineurin inhibitors.
- Topical calcineurin inhibitors are a reasonable and well-tolerated option for the treatment of pediatric periorificial dermatitis, either as monotherapy or in combination with other modalities.

How did this article change the practice of dermatology?

- Periorificial dermatitis is a common childhood condition that often occurs concurrently with atopic dermatitis but may be triggered or exacerbated by topical corticosteroids used to treat eczema.
- This retrospective study is the first to show that topical calcineurin inhibitors, alone and in combination with other medications, are a beneficial and well-tolerated treatment for periorificial dermatitis in a pediatric cohort.

 1
- The anti-inflammatory, steroid-sparing effects of topical calcineurin inhibitors fill a gap in the therapeutic armamentarium for periorificial dermatitis in children.

Funding sources: None.

Correspondence to: Julie V. Schaffer, MD, Hackensack University Medical Center, 155 Polifly Road, Suite 101, Hackensack, NJ 07601. E-mail: julie.schaffer@hmhn.org.

© 2021 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.

https://doi.org/10.1016/j.jaad.2021.02.008

Conflicts of interest

None disclosed.

REFERENCE

 Ollech A, Yousif R, Kruse L, et al. Topical calcineurin inhibitors for pediatric periorificial dermatitis. J Am Acad Dermatol. 2020; 82(6):1409-1414.